Biogen Inc.
Biogen Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
1 of 3 strong
The short version
- Growth products generated $851 million in Q1 2026, up 12% YoY, underpinning positive momentum. - Biogen expects continued top-line and bottom-line growth aligned with immunology and rare disease strategies, further bolstered by the Apellis acquisition.
From Biogen Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Growth products generated $851 million in Q1 2026, up 12% YoY, underpinning positive momentum.
- LEQEMBI market revenue rose 74% YoY to $168 million in Q1 2026, with strong growth in U.S., Japan, and China.
- SKYCLARYS revenue grew 22% YoY to $151 million globally, with expansion expected mainly outside the U.S.
- Anticipated meaningful contributions from Syfovre and Empaveli post-Apellis acquisition, enhancing top-line growth near and long term.
- Ongoing investments in late-stage pipeline programs (felzartamab, litifilimab, Salanersen) expected to boost future revenues.
- Multiple registrational data readouts planned over next 18 months, likely driving growth.
- Confident outlook on expanding in China through new rights acquisitions like felzartamab.
2 more points from Biogen Inc.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Biogen Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Biogen plans disciplined spending to support programs in its pipeline, including investments through business development (Page 5).
- The acquisition of Apellis is expected to close in Q2 2026, funded by $3.6 billion cash and $2 billion bank borrowings, with plans to repay borrowings by end of 2027 (Page 5).
- Investments include prelaunch activities supporting lupus and nephrology and direct-to-consumer advertising for VUMERITY and ZURZUVAE (Page 4).
- Biogen is building capacity through its commercial and patient services infrastructure, as highlighted in integration plans for Apellis products (Page 10).
2 more points from Biogen Inc.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Biogen Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The call transcript does not explicitly mention current, expected orderbook, or pending orders figures.
- However, it highlights strong commercial performance, with growth products generating $851 million in Q1 2026 revenue, up 12% year-over-year.
- Specific uptake noted for products like LEQEMBI, SKYCLARYS, and SPINRAZA with growth in patient demand globally.
- Emphasis on market growth especially outside the U.S., e.g., SKYCLARYS availability in 35 countries and LEQEMBI leading market share in U.S., Japan, and China.
2 more points from Biogen Inc.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
Biogen Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Biogen Inc. Q2 FY26 results?
- Growth products generated $851 million in Q1 2026, up 12% YoY, underpinning positive momentum. - Biogen expects continued top-line and bottom-line growth aligned with immunology and rare disease strategies, further bolstered by the Apellis acquisition.
What is Biogen Inc. share price analysis?
Biogen Inc. currently shows a below-average growth signal. The stock trades at a P/E of 20.8 with a market cap of $28,994. Investors should review the full earnings analysis for detailed insights.
Is Biogen Inc. planning capital expenditure?
- Biogen plans disciplined spending to support programs in its pipeline, including investments through business development (Page 5).
Keep Biogen Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.